Degrassi Alessia, Conticello Caren, Njimi Hassane, Coppalini Giacomo, Oliveira Fernando, Diosdado Alberto, Anderloni Marco, Jodaitis Lise, Schuind Sophie, Taccone Fabio Silvio, Gouvêa Bogossian Elisa
Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Neurology, HUB, ULB, Brussels, Belgium.
Neurocrit Care. 2025 Apr 28. doi: 10.1007/s12028-025-02270-9.
Numerous grading scales were proposed for subarachnoid hemorrhage (SAH) to assess the likelihood of unfavorable neurological outcomes (UO) and the risk of delayed cerebral ischemia (DCI). We aimed to validate the Hemorrhage, Age, Treatment, Clinical Status, and Hydrocephalus (HATCH) score and the VASOGRADE, a simple grading scale for prediction of DCI after aneurysmal SAH.
This was a retrospective single-center study of patients with nontraumatic SAH (January 2016 to December 2021) admitted to the intensive care unit. We performed a receiver operating characteristic (ROC) curve analysis to assess the discriminative ability of the HATCH and the VASOGRADE to identify patients who had UO at 3 months (defined as Glasgow Outcome Scale score of 1-3), hospital mortality, and DCI and compared their performance with the World Federation of Neurosurgical Surgeons, the modified Fisher, the Sequential Organ Failure Assessment, and the Acute Physiology and Chronic Health Evaluation II scales. We performed a multivariate logistic regression analysis to assess the association between HATCH and UO at 3 months and between VASOGRADE and DCI.
We included 262 consecutive patients with nontraumatic SAH. DCI was observed in 82 patients (31.3%), whereas 78 patients (29.8%) died during hospital stay and 133 patients (51%) had UO at 3 months. HATCH was independently associated with UO (odds ratio 1.61, 95% confidence interval [CI] 1.36-1.90) and had an area under the ROC curve (AUROC) of 0.83 (95% CI 0.77-0.88), comparable to the Acute Physiology and Chronic Health Evaluation II (AUROC 0.84, 95% CI 0.79-0.89) and Sequential Organ Failure Assessment (AUROC 0.83, 95% CI 0.77-0.88).
Hemorrhage, Age, Treatment, Clinical Status, and Hydrocephalus and VASOGARDE scores had a good performance to predict UO or in-hospital mortality and DCI, respectively; however, their performance did not outperform nonspecific routinely used scores.
针对蛛网膜下腔出血(SAH)提出了多种分级量表,以评估不良神经功能结局(UO)的可能性以及迟发性脑缺血(DCI)的风险。我们旨在验证出血、年龄、治疗、临床状态和脑积水(HATCH)评分以及VASOGRADE,一种用于预测动脉瘤性SAH后DCI的简单分级量表。
这是一项对入住重症监护病房的非创伤性SAH患者(2016年1月至2021年12月)进行的回顾性单中心研究。我们进行了受试者操作特征(ROC)曲线分析,以评估HATCH和VASOGRADE识别3个月时出现UO(定义为格拉斯哥预后量表评分为1-3)、医院死亡率和DCI患者的判别能力,并将它们的表现与世界神经外科医师联合会、改良Fisher、序贯器官衰竭评估和急性生理与慢性健康评估II量表进行比较。我们进行了多因素逻辑回归分析,以评估HATCH与3个月时的UO之间以及VASOGRADE与DCI之间的关联。
我们纳入了262例连续的非创伤性SAH患者。82例患者(31.3%)出现DCI,78例患者(29.8%)在住院期间死亡,133例患者(51%)在3个月时出现UO。HATCH与UO独立相关(比值比1.61,95%置信区间[CI]1.36-1.90),ROC曲线下面积(AUROC)为0.83(95%CI 0.77-0.88),与急性生理与慢性健康评估II(AUROC 0.84,95%CI 0.79-0.89)和序贯器官衰竭评估(AUROC 0.83,95%CI 0.77-0.88)相当。
出血、年龄、治疗、临床状态和脑积水以及VASOGARDE评分分别在预测UO或院内死亡率和DCI方面表现良好;然而,它们的表现并未优于常规使用的非特异性评分。